Thursday, 21 Mar 2019

You are here

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Nucala, an interleukin-5 antagonist monoclonal antibody, was previously approved in 2015 to treat severe asthma with an eosinophilic phenotype.  The current approval occurs because of an FDA priority review through the orphan drug program. Orphan drug designation provides incentives to assist and encourage the development of drugs for rare diseases.

Evidence for the efficacy of mepolizumab was established in a NEJM report (N Engl J Med 2017; 376:1921-1932) published in May 18, 2017.  This was a 52 week study of 136 patients with relapsing or refractory EGPA patients (on stable doses of steroids) who were given either 300 mg of mepolizumab or placebo every 4 weeks, for a year. The mepolizumab group had more remissions at both week 36 and week 48 (32% vs. 3%), had a 50% lower annualized relapse rate and more patients in the mepolizumab group (18%) were able to discontinue prednisone.

Although only half the participants treated with mepolizumab had protocol-defined remission, this novel biologic intervention represents a new and significant advance in the treatment of EGPA.

Nucala is administered as 300mg once every four weeks by subcutaneous injection

The most common adverse reactions associated with Nucala in clinical trials included headache, injection site reaction, back pain, and fatigue. There are warnings about the risk of herpes zoster, helminthic infections and avoidance during acute bronchospasm or status asthmaticus.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.